Načítá se...
Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload
BACKGROUND: The dual Na(+) and cardiac Ca(2+)-release channel inhibitor, Flecainide (FLEC) is effective in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), a disease caused by mutations in cardiac Ca(2+)-release channels (RyR2), calsequestrin (Casq2), or calmodulin. FLEC s...
Uloženo v:
| Vydáno v: | Front Physiol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6701460/ https://ncbi.nlm.nih.gov/pubmed/31456692 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphys.2019.00992 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|